CNSP insider filings
CNS Pharmaceuticals, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-08-18. Screen CNSP transaction legs live →
Insider transaction summary — last 90 days
2026-07-10 to 2026-10-08, from the filings listed below: 2 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing by 1 insider — 2,000 shares, $10,000 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 2.
- Largest priced transaction: purchase of 2,000 shares @ $5.00 ($10,000) by Fisher Michal, filed 2026-08-18.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Fisher Michal — Director | 1 | 1 leg · 2,000 sh · $10,000 | — | — |
| Levin Rami — CEO and President | 1 | — | — | 2 |
Recent insider filings — CNS Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-18 | 4 | Fisher Michal — Director | Purchase (P): 2,000 @ $5 | EDGAR |
| 2026-08-18 | 4 | Levin Rami — CEO and President | Option exercise (M): 4,750 @ $0 · Option exercise (M): 4,750 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | Charles Faith L. — Director | Purchase (P): 7,100 @ $4.79 | EDGAR |
| 2026-03-04 | 4 | Faulkner Eric — Chief Technology Officer | Grant/award (A): 9,500 (derivative) | EDGAR |
| 2026-03-04 | 4 | O'Loughlin Steve — Chief Financial Officer | Grant/award (A): 9,500 (derivative) | EDGAR |
| 2026-01-02 | 4 | Levin Rami — CEO and President, Director | Grant/award (A): 19,000 (derivative) | EDGAR |
| 2025-11-19 | 4 | Cockroft Bettina M. — Director | Grant/award (A): 1,517 (derivative) @ $0 | EDGAR |
| 2025-11-19 | 4 | Mahery Amy — Director | Grant/award (A): 1,517 (derivative) @ $0 | EDGAR |
| 2025-11-19 | 4 | Charles Faith L. — Director | Grant/award (A): 1,517 (derivative) @ $0 | EDGAR |
| 2025-11-19 | 4 | Gumulka Jerzy — Director | Grant/award (A): 1,517 (derivative) @ $0 | EDGAR |
| 2025-11-19 | 4 | Downs Christopher — Chief Financial Officer | Grant/award (A): 4,881 (derivative) @ $0 | EDGAR |
| 2025-11-19 | 4 | Keyes Jeffry R. — Director | Grant/award (A): 1,517 (derivative) @ $0 | EDGAR |
| 2025-11-19 | 4 | Climaco John M — Chief Executive Officer, Director | Grant/award (A): 9,761 (derivative) @ $0 | EDGAR |
| 2024-08-06 | 4 | Cortice Biosciences, Inc. — 10% owner | Holdings only — no transactions reported | EDGAR |
| 2024-04-10 | 4 | Charles Faith L. — Director | Grant/award (A): 17,500 (derivative) · Grant/award (A): 17,500 (derivative) | EDGAR |
| 2024-04-10 | 4 | Mahery Amy — Director | Grant/award (A): 17,500 (derivative) · Grant/award (A): 17,500 (derivative) | EDGAR |
| 2024-04-10 | 4 | Gumulka Jerzy — Director | Grant/award (A): 17,500 (derivative) · Grant/award (A): 17,500 (derivative) | EDGAR |
| 2024-04-10 | 4 | Evans Carl Anthony — Director | Grant/award (A): 17,500 (derivative) · Grant/award (A): 17,500 (derivative) | EDGAR |
| 2024-04-10 | 4 | Cockroft Bettina M. — Director | Grant/award (A): 17,500 (derivative) · Grant/award (A): 17,500 (derivative) | EDGAR |
| 2024-04-10 | 4 | Downs Christopher — Chief Financial Officer | Grant/award (A): 40,000 (derivative) · Grant/award (A): 40,000 (derivative) | EDGAR |
| 2024-04-10 | 4 | Keyes Jeffry R. — Director | Grant/award (A): 17,500 (derivative) · Grant/award (A): 17,500 (derivative) | EDGAR |
| 2024-04-10 | 4 | Climaco John M — Chief Executive Officer, Director | Grant/award (A): 83,000 (derivative) · Grant/award (A): 83,000 (derivative) | EDGAR |
| 2024-02-06 | 4 | Mahery Amy — Director | Grant/award (A): 12,420 (derivative) | EDGAR |
| 2024-02-06 | 4 | Gumulka Jerzy — Director | Purchase (P): 33,333 @ $0.30 · Grant/award (A): 33,333 (derivative) · Grant/award (A): 33,333 (derivative) | EDGAR |
| 2024-02-06 | 4 | Evans Carl Anthony — Director | Purchase (P): 33,333 @ $0.30 · Grant/award (A): 33,333 (derivative) · Grant/award (A): 33,333 (derivative) | EDGAR |
| 2024-02-06 | 4 | Downs Christopher — Chief Financial Officer | Purchase (P): 66,666 @ $0.30 · Grant/award (A): 66,666 (derivative) · Grant/award (A): 66,666 (derivative) | EDGAR |
| 2024-02-06 | 4 | Climaco John M — Chief Executive Officer, Director | Purchase (P): 166,666 @ $0.30 · Grant/award (A): 166,666 (derivative) · Grant/award (A): 166,666 (derivative) | EDGAR |
| 2023-10-12 | 4/A | Gumulka Jerzy — Director | Grant/award (A): 39,475 (derivative) | EDGAR |
| 2023-10-12 | 4/A | Evans Carl Anthony — Director | Grant/award (A): 39,475 (derivative) | EDGAR |
| 2023-10-12 | 4/A | Cockroft Bettina M. — Director | Grant/award (A): 6,500 (derivative) · Grant/award (A): 9,475 (derivative) | EDGAR |
| 2023-10-12 | 4/A | Charles Faith L. — Director | Grant/award (A): 26,315 (derivative) | EDGAR |
| 2023-10-12 | 4/A | Andraczke Andrzej — Director | Grant/award (A): 39,475 (derivative) | EDGAR |
| 2023-10-12 | 4/A | Keyes Jeffry R. — Director | Grant/award (A): 39,475 (derivative) | EDGAR |
| 2023-09-25 | 4 | Gumulka Jerzy — Director | Grant/award (A): 68,961 (derivative) | EDGAR |
| 2023-09-25 | 4 | Evans Carl Anthony — Director | Grant/award (A): 68,961 (derivative) | EDGAR |
| 2023-09-25 | 4 | Cockroft Bettina M. — Director | Grant/award (A): 16,551 (derivative) | EDGAR |
| 2023-09-25 | 4 | Charles Faith L. — Director | Grant/award (A): 45,974 (derivative) | EDGAR |
| 2023-09-25 | 4 | Andraczke Andrzej — Director | Grant/award (A): 68,961 (derivative) | EDGAR |
| 2023-09-25 | 4 | Keyes Jeffry R. — Director | Grant/award (A): 68,961 (derivative) | EDGAR |
| 2023-08-23 | 4 | Downs Christopher — Chief Financial Officer | Purchase (P): 27,000 @ $1.27 | EDGAR |
| 2023-08-16 | 4 | Climaco John M — Chief Executive Officer, Director | Purchase (P): 2,750 @ $1.80 | EDGAR |
| 2023-08-10 | 4/A | Cockroft Bettina M. — Director | Grant/award (A): 2,099 (derivative) | EDGAR |
| 2023-08-01 | 4 | Priebe Waldemar — 10% owner | Sale (S): 5,500 @ $2.47 · Sale (S): 5,500 @ $2.46 · Sale (S): 5,500 @ $2.40 · Sale (S): 2,798 @ $2.43 · Sale (S): 5,000 @ $1.29 · Sale (S): 5,000 @ $1.30 · +11 more | EDGAR |
| 2023-05-09 | 4 | Cockroft Bettina M. — Director | Grant/award (A): 8,300 (derivative) | EDGAR |
| 2023-05-01 | 4 | Downs Christopher — Chief Financial Officer | Option exercise (M): 521 · Option exercise (M): 521 (derivative) | EDGAR |
| 2023-05-01 | 4 | Climaco John M — Chief Executive Officer, Director | Option exercise (M): 1,250 · Option exercise (M): 1,250 (derivative) | EDGAR |
| 2023-04-21 | 4 | Gumulka Jerzy — Director | Purchase (P): 2,500 @ $1.70 | EDGAR |
| 2023-04-18 | 4 | Downs Christopher — Chief Financial Officer | Purchase (P): 3,100 @ $3.20 | EDGAR |
| 2023-04-17 | 4 | Gumulka Jerzy — Director | Purchase (P): 7,173 @ $0.74 | EDGAR |
| 2023-04-14 | 4 | Climaco John M — Chief Executive Officer, Director | Purchase (P): 15,000 @ $0.69 | EDGAR |
Recent 8-K events — CNS Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-10-02 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-02 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-11 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-02 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-17 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-17 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-21 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-22 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-15 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CNSP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →